cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

Publisher： Bentham Science Publishers

E-ISSN： 1875-6190|9|4|715-727

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.9, Iss.4, 2011-12, pp. : 715-727

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

By Kruuse C.   Rybalkin S.D.   Khurana T.S.   Jansen-Olesen I.   Olesen J.   Edvinsson L.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 55-65

Elsevier

Access to resources Recommend Favorite

Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

By Sybertz E.   Czarniecki M.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. : 631-639

Informa Healthcare

Access to resources Recommend Favorite

Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium

By Weninger Sabine   Maeyer Joris   Lefebvre Romain  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 386, Iss. 8, 2013-08 ,pp. : 671-684

Springer Publishing Company

Access to resources Recommend Favorite

Vilazodone: In Major Depressive Disorder

By Frampton James E.  

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 615-627

Adis International

Access to resources Recommend Favorite

Aripiprazole: In Major Depressive Disorder

By Weber Juliane   Lyseng-Williamson Katherine A.   Scott Lesley J.  

CNS Drugs, Vol. 22, Iss. 10, 2008-01 ,pp. : 807-813

Adis International

Access to resources Recommend Favorite